Eli Lilly to double its manufacturing capacity for Mounjaro as it faces financial headwinds going into 2023 — report

Eli Lilly is facing several financial headwinds going into next year, spurred by the drying up of Covid-19 antibody sales and supply constraints, according to a report from SVB Securities by three of its analysts who visited Eli Lilly’s headquarters in Indianapolis last week.

An anticipated “stepdown” in Covid-19 antibody…
Click here to view original post